Table 2.

Coughing values during microinjections of (−)nicotine into the caudal ventral respiratory column area

	Control	Microinjection, %Control	>10 min Later, %Control
CN, no.	3.41 ± 0.48	53 ± 11b	99 ± 8e
MN	5.56 ± 1.16	75 ± 7a	99 ± 11
PS ips, %	90 ± 6	65 ± 7a	88 ± 11d
MN	70 ± 15	50 ± 14	78 ± 13d
PS con, %	92 ± 4	66 ± 8a	99 ± 11d
MN	117 ± 22	107 ± 46	201 ± 99
EP I, cmH2O	−6.37 ± 1.22	103 ± 11	108 ± 10
MN	−6.97 ± 1.52	76 ± 11a	93 ± 11d
ABD ips, %	100 ± 15	51 ± 10b	93 ± 13e
MN	83 ± 18	46 ± 10a	86 ± 23d
ABD con, %	99 ± 12	48 ± 10b	92 ± 15e
MN	79 ± 15	43 ± 8b	81 ± 16e
EP E, cmH2O	14.24 ± 2.76	53 ± 10b	79 ± 7d
MN	11.13 ± 3.30	57 ± 15c	104 ± 8f
CTI, s	1.37 ± 0.13	116 ± 6	108 ± 10
CTE, s	2.08 ± 0.32	119 ± 10b	97 ± 5d
CTE1, s	0.97 ± 0.15	91 ± 7	101 ± 7
CTE2, s	1.13 ± 0.28	134 ± 24a	100 ± 8
TABD, s	1.11 ± 0.24	71 ± 11a	92 ± 7
Overlap, s	0.39 ± 0.11	47 ± 13b	78 ± 9d
CTtot, s	3.45 ± 0.38	118 ± 8a	101 ± 6

Values are means ± SE; n = 8 cats (n = 5 cats for MN values). MN, postnicotine data after MEC microinjections; CN, number of coughs per 10 s stimulation; ips, ipsilateral; con, contralateral; ABD, amplitudes of abdominal muscle EMG; EP E, expiratory amplitudes of esophageal pressure; CT_I, duration of inspiratory phase; CT_E, CT_E1, and CT_E2, durations of cough expiratory, active expiratory, and passive expiratory phase, respectively; TABD, duration of cough abdominal muscles activity; Overlap, overlapping of PS and ABD cough related activity; CTtot, duration of the total cough cycle.

^aP < 0.05,

^bP < 0.01,

^cP < 0.001 vs. control.

^dP < 0.05,

^eP < 0.01,

^fP < 0.001 vs. (−)NIC microinjection data.